We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.20 | -0.83% | 143.40 | 142.80 | 143.40 | 147.00 | 143.40 | 147.00 | 67,195 | 09:36:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 65.12M | -65.7M | -0.2744 | -5.28 | 346.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/12/2024 07:57 | A company more likely to bid £1 billion now than want a commercial deal in a years time after a phase three trial .With cash in bank and royalties to come you would get your £1 billion back with in 5 years with lyt100 producing big cash . | doctor 69 | |
19/12/2024 14:55 | Perhaps the firm needs to provide the annual update on 24.12 after the inevitable stock dump "With analysts forecasting peak LYT-100 sales of $800m per annum on a successful Phase 3 and commercial launch , a potential valuation of c $1.5b to $2b for LYT-100 appears reasonable. Throw in everything else in Puretech from current cash, future royalties from BMS , Seaport and Gallop plus Vedanta et al , and you have a potentially $3/4b enterprise in perhaps 2 years or so.But Mr Market just yawns .However Puretech is now more vulnerable to a bid than ever before imho." from a poster on LSE nai etc | takeiteasy | |
19/12/2024 14:36 | Trackers...it's coming out of the ftse 250 on 23/12.looks stunning to me. | colinblackbourn | |
19/12/2024 14:36 | Played like a fiddle for months | brianblu | |
19/12/2024 14:33 | short term, the share has not decided whether it is coming or going - selling off like it has had some sort of profit warning rather than the opposite...can only imagine some large holders have to reduce position sizes for wider reasons ? | takeiteasy | |
19/12/2024 08:01 | Superb listen , this could ten bag over next few yrs in my opinion | doctor 69 | |
19/12/2024 07:35 | Couple of new projects not yet public.excellent clip.explains a lot. | colinblackbourn | |
19/12/2024 06:44 | https://www.biotecht | colinblackbourn | |
18/12/2024 16:27 | The US Jefferies analyst is forecasting peak sales of $10bn pa.The UK analyst $3.5bn...maybe they should speak to each other. | colinblackbourn | |
18/12/2024 16:14 | edit- more later if I can | jaws6 | |
18/12/2024 15:53 | hmm cobenfy should be way north of that - i assume they are just forecasting US alone with that number | edwardt | |
18/12/2024 15:32 | Jeffries note forecasts peak sales LYT 100 $800m pa with a probability of 40pc.Peak sales Cobenfy $3.5bn. | colinblackbourn | |
18/12/2024 13:17 | LYT100 is in for free ....as is the massive upside for Seaport. | colinblackbourn | |
18/12/2024 12:39 | hxxps://in.investing | jaws6 | |
18/12/2024 12:38 | hxxps://firstwordpha | jaws6 | |
18/12/2024 12:37 | pretty clear then i think from this link and the PRTC presentation...have to believe despite DT in USA this can move.... | takeiteasy | |
18/12/2024 12:01 | www.marketbeat.com/i | jaws6 | |
18/12/2024 10:54 | jaws, try to remove https or www refs and link will stick I think | takeiteasy | |
18/12/2024 10:51 | Year end cash should be $340m as forecast plus $29m Cobenfy milestones less $14m put into Seaport.Seaport has $325m cash with PureTech holding now 37pc. | colinblackbourn | |
18/12/2024 10:43 | Re Cobenfy.we will get $373m in tranches as sales go to $2bn.anything above that we get 2pc. | colinblackbourn | |
18/12/2024 10:14 | can not post link here for some reason but it is in marketbeat | jaws6 | |
18/12/2024 10:13 | link- [...] | jaws6 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions